MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
407
Employees407
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
407
Employees407

MNKD Key Statistics

Market cap
1.68B
Market cap1.68B
Price-Earnings ratio
57.90
Price-Earnings ratio57.90
Dividend yield
Dividend yield
Average volume
4.21M
Average volume4.21M
High today
$5.98
High today$5.98
Low today
$5.46
Low today$5.46
Open price
$5.88
Open price$5.88
Volume
4.52M
Volume4.52M
52 Week high
$6.51
52 Week high$6.51
52 Week low
$3.38
52 Week low$3.38

Stock Snapshot

As of today, MannKind(MNKD) shares are valued at $5.57. The company's market cap stands at 1.68B, with a P/E ratio of 57.90.

On 2026-01-24, MannKind(MNKD) stock traded between a low of $5.46 and a high of $5.98. Shares are currently priced at $5.57, which is +2.1% above the low and -6.9% below the high.

MannKind(MNKD) shares are trading with a volume of 4.52M, against a daily average of 4.21M.

During the past year, MannKind(MNKD) stock moved between $3.38 at its lowest and $6.51 at its peak.

During the past year, MannKind(MNKD) stock moved between $3.38 at its lowest and $6.51 at its peak.

MNKD News

Simply Wall St 2d
MannKind Maps 2026 FDA Catalysts for Afrezza and FUROSCIX ReadyFlow Autoinjector Narrative

MannKind Corporation recently outlined its 2026 growth drivers, emphasizing upcoming FDA milestones for Afrezza, including label updates to simplify adult dosin...

MannKind Maps 2026 FDA Catalysts for Afrezza and FUROSCIX ReadyFlow Autoinjector Narrative
Simply Wall St 4d
Assessing MannKind Valuation After Recent Revenue And Profit Results

Advertisement Why MannKind (MNKD) is on investors’ radar MannKind (MNKD) has attracted attention after posting annual revenue of US$313.787 million and net in...

Assessing MannKind Valuation After Recent Revenue And Profit Results

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.